Europäische Union - Estnisch - EMA (European Medicines Agency)

recordati rare diseases - tsink - hepatolentikulaarne degeneratsioon - muud alimentary seedetrakti ja ainevahetust tooted, - wilsoni tõve ravi.

Estland - Estnisch - Ravimiamet

pierre fabre medicament - raud(ii)sulfaat - toimeainet prolongeeritult vabastav tablett - 247,25mg 90tk; 247,25mg 30tk

Estland - Estnisch - Ravimiamet

actavis nordic a/s - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 1000mg+500mg 10tk

Estland - Estnisch - Ravimiamet

actavis group ptc ehf. - ampitsilliin+sulbaktaam - süste-/infusioonilahuse pulber - 2000mg+1000mg 10tk

Estland - Estnisch - Ravimiamet

pierre fabre medicament - raud(ii)sulfaat - suukaudne lahus - 20mg 1ml 90ml 1tk

Estland - Estnisch - Ravimiamet

g.l. pharma gmbh - raud(ii)fumaraat+foolhape+askorbiinhape - kõvakapsel - 202,8mg+0,8mg+100mg 100tk; 202,8mg+0,8mg+100mg 30tk; 202,8mg+0,8mg+100mg 56tk; 202,8mg+0,8mg+100mg 84tk; 202,8mg+0,8mg+100mg 28tk; 202,8mg+0,8mg+100mg 98tk; 202,8mg+0,8mg+100mg 20tk; 202,8mg+0,8mg+100mg 60tk

Europäische Union - Estnisch - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Estland - Estnisch - Ravimiamet

kalceks as - tiamiin+püridoksiin+tsüanokobalamiin+lidokaiin - süstelahus - 50mg+50mg+0,5mg+10mg 1ml 2ml 10tk; 50mg+50mg+0,5mg+10mg 1ml 2ml 5tk

Europäische Union - Estnisch - EMA (European Medicines Agency)

teva pharma b.v. - leflunomiid - artriit, reumatoidartriit - immunosupressandid - leflunomiid on näidustatud aktiivse reumatoidartriidiga täiskasvanud patsientide raviks "haigust modifitseerivate reumavastaste ravimitega" (dmard). hiljutine või samaaegne ravi hepatotoxic või haematotoxic dmards e. metotreksaat) võib suurendada tõsiste kõrvaltoimete esinemise riski; seetõttu tuleb leflunomiidiravi alustamist nende kasu / riski aspektide osas hoolikalt kaaluda. lisaks sellele üleminek leflunomiidi teise dmard ilma pärast washout menetluse võib suureneda ka risk tõsiste kõrvaltoimete isegi pikka aega pärast lülitus.

Europäische Union - Estnisch - EMA (European Medicines Agency)

norgine b.v. - raud maltool - aneemia, raud-defitsiit - antianemilised preparaadid - feraccru on näidustatud täiskasvanute raviks rauapuuduse.